Table 6:
Comparison of demographic and clinico-pathologic parameters between cFSGS in allografts and native kidneys
|
De novo Post-KT cFSGS (n=38) |
native cFSGS controls (n=255) |
P values | |
|---|---|---|---|
| Demographic and clinical parameters | |||
| Age (years) | 57 (47, 65) | 46 (34, 60) | P=0.005 |
| Female gender | 13/38 (34%) | 119/255 (47%) | P=0.17 |
| AA recipients/patients1 | 10/38 (26%) | 157/225 (70%) | P<0.001 |
| Serum Cr at biopsy (mg/dL) | 5.4 (3.4, 6.8) | 4.0 (2.2, 6.8) | P=0.09 |
| Urine protein/Cr at biopsy (g/g)2 | 3.5 (1.3, 6.5) | 7.0 (4.1, 12.0) | P<0.001 |
| Serum albumin at biopsy (g/dL)3 | 3.2 (2.8, 3.7) | 2.4 (1.8, 3.0) | P<0.001 |
| Nephrotic proteinuria2 | 19/37 (51%) | 209/249 (84%) | P<0.001 |
| Nephrotic syndrome4 | 7/38 (18%) | 91/220 (41%) | P=0.007 |
| Traditional causes 5 Viral Acute VOD IFN treatment Pamidronate treatment |
15/38 (39%) 5/38 (13%) - HIV: 0/38 (0%) 11/38 (29%) 0/38 (0%) 0/38 (0%) |
87/255 (34%) 2 67/255 (26%) - HIV: 58/255 (23%) 13/255 (5%) 3/255 (1%) 4/255 (2%) |
P=0.592 P=0.11 P<0.001 P<0.001 P=1.00 P=1.00 |
| Pathology parameters | |||
| Global GS (%) | 11 (0, 25) | 21 (6, 41) | P=0.01 |
| Collapsed Glom (%) | 14 (8, 19) | 17 (8, 31) | P=0.15 |
| IFTA (%) | 25 (6, 44) | 40 (20, 65) | P=0.002 |
| Glom PDs | 31/38 (82%) | 193/255 (76%) | P=0.19 |
| FPE (%)6 - Focal - Extensive - Diffuse |
70 (48, 93) 2/8 (25%) 3/8 (37.5%) 3/8 (37.5%) |
90 (60, 100) 31/161 (19%) 40/161 (25%) 90/161 (56%) |
P=0.45 |
| Prominent tubular PDs | 16/38 (42%) | 78/255 (31%) | P=0.19 |
| Tubular microcysts | 5/38 (13%) | 90/255 (35%) | P=0.005 |
| Arteriosclerosis (0–3) | 1 (1, 2) [1.4 ±0.9] | 2 (1, 2) [1.5 ±0.9] | P=0.54 |
| Arteriolosclerosis (0–3) | 1 (1, 2) [1.3 ±0.9] | 2 (1, 2)][1.4 ±0.9] | P=0.25 |
Abbreviations: AA; African American; Cr, creatinine; Glom, glomeruli; GS, glomerulosclerosis; FPE, foot process effacement; IFN, Interferon; IFTA, interstitial fibrosis/tubular atrophy; NA, not available; PDs, protein droplets; VOD, vaso-occlusive disease
Semi-quantitative values were presented as median (IQR1, IQR3) and mean ±SD
Data on race is not available for 30 native controls
Data on proteinuria is unavailable for 1 post-KTx cFSGS and 6 native controls
Data on serum albumin is unavailable for 29 native controls
Data on nephrotic syndrome is not available for 35 native controls
Viral infections in post-KTx cFSGS (n=5) included 3 CMV 1 Parvovirus & 1 EBV while these in native controls (n=67) included 58 HIV, 7 Parvovirus, 1 CMV & 1 EBV
Data on FPE was available for 8 post-KTx cFSGS and 161 native controls